CD74 and lymphoma: Regarding the MIF receptor, milatuzumab, a humanized anti-CD74 antibody, has clinical activity on lymphomas and has been tested in vitro with some success as an antibody-drug conjugate on solid cancer cell lines positive for CD74 (21).